More on the impact of American Academy of Pediatrics palivizumab guidance for infants with respiratory syncytial virus infection

According to the 2014 American Academy of Pediatrics (AAP) recommendations, preterm infants born at ≥29 weeks' gestational age (WGA) no longer qualify for palivizumab prophylaxis, unless they have additional risks.1 To evaluate the effects of this AAP restriction on respiratory syncytial virus (RSV) infections, Zembles et al2 compared data on RSV-associated hospitalizations (RSVaH) related to 2 seasons before (pre-AAP) and 3 seasons after (post-APP) the implementation of the revised recommendations.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Letters to the Editor Source Type: research